Colossal Biosciences’ next raise could price de‑extinction at up to $30B

Colossal Biosciences is reportedly in discussions to raise another venture round that would value the company somewhere between $20 billion and $30 billion, potentially doubling or even tripling its last private valuation.

The company is known for pursuing de-extinction — using advanced biotechnology to bring back lost species and engineer related conservation tools. While names and numbers for the prospective round have not been disclosed, the target valuation range alone puts Colossal in territory more commonly associated with late-stage software platforms than with frontier biology startups.

Colossal’s work sits at the intersection of synthetic biology, conservation, and deep tech R&D. De-extinction is not just about resurrecting animals from the past; it touches on techniques that could reshape how ecosystems are restored, how biodiversity is preserved, and how genetic tools are applied to climate and environmental challenges. The company’s ambitions place it in a category where time horizons are long, capital needs are substantial, and scientific as well as regulatory risk is high — but where the upside, if successful, could be transformative.

From what has been reported so far, Colossal is not simply topping up its balance sheet — it is actively testing whether investors are willing to underwrite a step-change in valuation. The suggested range of $20 billion to $30 billion implies a multiple of up to three times its previous mark, signaling confidence either in recent technical progress, in the scalability of its platform, or in expanding commercial optionality around its science. Details on participating investors, deal size, and exact stage have not yet been made public.

For founders working in hard science and deep tech, this potential jump in valuation is a notable data point. It suggests that, even in capital-intensive and long-gestation fields like de-extinction and advanced bioengineering, there is still room for aggressive pricing when a story captures both technological imagination and perceived market potential. It also underscores how frontier biology narratives — climate resilience, biodiversity restoration, and novel genetic capabilities — can command late-stage software-style valuations when investors believe they are backing a category-defining platform rather than a single product.

What happens next will be important to watch. If Colossal closes a round at the upper end of the indicated range, it could reset valuation expectations for a broader cohort of synthetic biology and conservation-tech startups, but it will also raise the bar on milestones the company must hit in the coming years. Translating headline valuation into sustained progress will require visible scientific breakthroughs, credible paths to commercialization, and careful management of public and regulatory scrutiny around de-extinction efforts. Until the round is formally announced, founders and investors alike will be watching to see whether this ambitious price tag turns into a completed deal — and how the market reacts once it does.